about
Anticholinergic agents for chronic asthma in adultsPharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airwaysTiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial AsthmaStrategies in managing asthma.Muscarinic receptor antagonists: effects on pulmonary function.Inhibition of inhaled metabisulphite-induced bronchoconstriction by inhaled frusemide and ipratropium bromideComparative study of the bronchodilating effects of (-)- and (+)-oxyphenonium bromide.The use of ipratropium bromide for the management of acute asthma exacerbation in adults and children: a systematic review.Pharmacological characteristics of liriodenine, isolated from Fissistigma glaucescens, a novel muscarinic receptor antagonist in guinea-pigsInhaled bronchodilator use for infants with bronchopulmonary dysplasia.A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study GroupAcute severe asthma.Pharmacological justification of use of Solena heterophylla Lour. in gastrointestinal, respiratory and vascular disorders.Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease.Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial.Effect of four weeks' high dose ipratropium bromide treatment on lung mucociliary clearanceFailure of ipratropium bromide to modify the diurnal variation of asthma in asthmatic children.Is nocturnal asthma caused by changes in airway cholinergic activity?Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing.Vagal Afferent Innervation of the Airways in Health and Disease.Pretreatment with antibody to eosinophil major basic protein prevents hyperresponsiveness by protecting neuronal M2 muscarinic receptors in antigen-challenged guinea pigs.Therapeutic management of allergic diseases.Perioperative management of the asthmatic patient.β-blockers and their mortality benefits: underprescribed in heart failure and chronic obstructive pulmonary disease.The role of anticholinergic bronchodilators in adult asthma and chronic obstructive pulmonary disease.The role of anticholinergic antimuscarinic bronchodilator therapy in children.Autonomic neural control of intrathoracic airways.Beta-Adrenergic AgonistsAsthma: 2. Trends in pharmacologic therapy.Transdermal scopolamine in the treatment of asthma: a preliminary report.Chest diseases: use of anticholinergic drugs for asthma.Anticholinergic antimuscarinic agents in the treatment of airways bronchoconstriction in children.Selective muscarinic receptor agonists and antagonists.Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease.Nebulisers for chronic obstructive pulmonary disease.Internal medicine: use of ipratropium bromide in chronic obstructive pulmonary disease.Effect of different bronchodilators on airway smooth muscle responsiveness to contractile agents.Neuronal muscarinic receptors attenuate vagally-induced contraction of feline bronchial smooth muscle.Acute severe asthma: new approaches to assessment and treatment.Efficacy of inhaled anticholinergics and anesthesia in treatment of a patient in status asthmaticus.
P2860
Q24246697-773F3C15-B8F3-46D3-A18F-F82F96CA8166Q24672158-57AF09C1-8B1C-430A-89ED-11173AF8FA25Q26780553-889B2CFE-3DD7-4BC1-8442-BA576DA01C11Q33616246-CB19973C-1498-4673-BEC2-8859F4D1A1E6Q33923361-9B40A776-976E-4966-80A8-410B51AC271DQ34403136-4865496B-3487-4595-BAC4-3FED5614AC53Q34417521-1D51F8CF-D1D8-465F-8720-BF9CB013B3A7Q34443155-CF5DF9DA-9D0F-49E2-8BE7-BA9E8F1B3AC2Q34792244-4CA89F45-C77A-447C-9737-D85BC0C80B11Q34797709-9CF2D89A-4150-4D15-989F-DD3BEB703567Q35533708-7D6347AE-0FEA-4009-B8C7-3FA84DABA799Q35548946-D94564D8-BA9E-4038-8512-91937CC9D25FQ35579104-1F84D79C-DFD5-4303-8D98-2C5B203AE729Q35841607-764B7E82-CCBC-44F0-ADF4-9AD91296B11BQ36003938-BAE53476-33D7-4966-914F-77C4C380A634Q36154134-F931E91F-81B5-4127-AD79-A625A75ADF00Q36166818-0EDCDFD0-07BA-4251-B159-C04F775761F3Q36188242-A3E6C6DB-7F8E-4595-9EA9-F48360C12353Q37151236-FE228C9B-299E-4DDE-BA2B-C9DCC91A2429Q37169500-EE555DFE-D27A-44CE-9C3C-4AA2673310D8Q37374262-97B53D53-E5E4-4FF6-A101-AC782CC8C1F6Q37550543-7FCF8FDC-7EAB-4065-B74C-625179B3B5A2Q37769888-4881A27C-0D95-4B99-89D2-9CC7FF6149EEQ37822723-B580F80F-6F9A-493E-A846-33C5F8CBB125Q37857423-2CF93C38-AAC9-4871-83C3-BDAC432A4E70Q37857426-1B821289-26A5-4271-802C-4D4FC4F3D6EAQ38116834-2EFB92C6-4F76-40E1-9DF9-C05FBBED958FQ38974241-82F925B5-19F1-484D-A7D9-C5D5F2F5F51FQ39461647-755FFB92-440C-486A-8284-BB3984A888A2Q39545446-4402CEDB-F72C-4F9E-A47E-497B8337E2C4Q40366165-F7571938-1AED-498F-83F2-49A3AEDE4F00Q41043361-F0AB4DD0-8474-47C3-84DB-3DC6A38DA574Q41122115-4DA6276A-6657-44E9-AA13-80CC89AC87C5Q41231716-8C84AAAD-EF42-4588-9413-70B4721BA79DQ41964597-CEE1473E-5C63-49E1-9310-4E0B19A3CB09Q42086952-B1C14207-B446-43D6-8864-C7CE095A8D41Q42089057-6212C13B-0912-4CB6-B71D-A65E92CEA587Q42115957-C43E57AD-2A61-4D79-81D1-68B6872F80D4Q43242771-E62A4F9A-9E76-4365-ADAF-49C22FF44993Q43908986-D347E0D9-D1E4-4554-9A37-9F8957DF3E4A
P2860
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
1984年论文
@zh
1984年论文
@zh-cn
name
Anticholinergic, antimuscarinic bronchodilators.
@en
type
label
Anticholinergic, antimuscarinic bronchodilators.
@en
prefLabel
Anticholinergic, antimuscarinic bronchodilators.
@en
P1476
Anticholinergic, antimuscarinic bronchodilators.
@en
P2093
P304
P356
10.1164/ARRD.1984.129.5.856
P577
1984-05-01T00:00:00Z